Literature DB >> 21920334

Myocardium at risk in ST-segment elevation myocardial infarction comparison of T2-weighted edema imaging with the MR-assessed endocardial surface area and validation against angiographic scoring.

Georg Fuernau1, Ingo Eitel, Vinzenz Franke, Lysann Hildebrandt, Josefine Meissner, Suzanne de Waha, Philipp Lurz, Matthias Gutberlet, Steffen Desch, Gerhard Schuler, Holger Thiele.   

Abstract

OBJECTIVES: The objective of this study was to assess the area at risk (AAR) in ST-segment elevation myocardial infarction with 2 different cardiac magnetic resonance (CMR) imaging methods and to compare them with the validated angiographic Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease Score (APPROACH-score) in a large consecutive patient cohort.
BACKGROUND: Edema imaging with T(2)-weighted CMR and the endocardial surface area (ESA) assessed by late gadolinium enhancement have been introduced as relatively new methods for AAR assessment in ST-segment elevation myocardial infarction. However, data on the utility and validation of these techniques are limited.
METHODS: A total of 197 patients undergoing primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction were included. AAR (assessed with T(2)-weighted edema imaging and the ESA method), infarct size, and myocardial salvage (AAR minus infarct size) were determined by CMR 2 to 4 days after primary angioplasty. Angiographic AAR scoring was performed by use of the APPROACH-score. All measurements were done offline by blinded observers.
RESULTS: The AAR assessed by T(2)-weighted imaging showed good correlation with the angiographic AAR (r = 0.87; p < 0.001), whereas the ESA showed only a moderate correlation either to T(2)-weighted imaging (r = 0.56; p < 0.001) or the APPROACH-score (r = 0.44; p < 0.001). Mean AAR by ESA (20.0 ± 11.7% of left ventricular mass) was significantly (p < 0.001) smaller than the AAR assessed by T(2)-weighted imaging (35.6 ± 10.9% of left ventricular mass) or the APPROACH-score (27.9 ± 10.5% of left ventricular mass) and showed a significant negative dependence on myocardial salvage index. In contrast, no dependence of T(2)-weighted edema imaging or the APPROACH-score on myocardial salvage index was seen.
CONCLUSIONS: The AAR can be reliably assessed by T(2)-weighted CMR, whereas assessment of the AAR by ESA seems to be dependent on the degree of myocardial salvage, thereby underestimating the AAR in patients with high myocardial salvage such as aborted infarction. Thus, assessment of the AAR with the ESA method cannot be recommended. (Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein [LIPSIA-N-ACC]; NCT00463749).
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920334     DOI: 10.1016/j.jcmg.2011.02.023

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  19 in total

1.  Can we still rely on the ECG for detecting past myocardial injury?

Authors:  Gautam G Lalani; Andrew M Kahn; Sanjiv M Narayan
Journal:  JACC Cardiovasc Imaging       Date:  2013-02-20

2.  Controversies in cardiovascular MR imaging: reasons why imaging myocardial T2 has clinical and pathophysiologic value in acute myocardial infarction.

Authors:  Andrew E Arai; Steve Leung; Peter Kellman
Journal:  Radiology       Date:  2012-10       Impact factor: 11.105

3.  Angiographic validation of magnetic resonance assessment of myocardium at risk in non-ST-elevation myocardial infarction.

Authors:  Dominik Buckert; Manuela Mariyadas; Thomas Walcher; Volker Rasche; Jochen Wöhrle; Wolfgang Rottbauer; Peter Bernhardt
Journal:  Int J Cardiovasc Imaging       Date:  2013-04-02       Impact factor: 2.357

4.  Prediction of functional recovery after primary PCI using the estimate of myocardial salvage in gated SPECT early after acute myocardial infarction.

Authors:  Raffaella Calabretta; Angelo Castello; Flavia Linguanti; Francesca Tutino; Alfonso Ciaccio; Cristina Giglioli; Roberto Sciagrà
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-01       Impact factor: 9.236

5.  Quantifying the Area at Risk in Reperfused ST-Segment-Elevation Myocardial Infarction Patients Using Hybrid Cardiac Positron Emission Tomography-Magnetic Resonance Imaging.

Authors:  Heerajnarain Bulluck; Steven K White; Georg M Fröhlich; Steven G Casson; Celia O'Meara; Ayla Newton; Jennifer Nicholas; Peter Weale; Simon M Y Wan; Alex Sirker; James C Moon; Derek M Yellon; Ashley Groves; Leon Menezes; Derek J Hausenloy
Journal:  Circ Cardiovasc Imaging       Date:  2016-03       Impact factor: 7.792

6.  Towards stratifying ischemic components by cardiac MRI and multifunctional stainings in a rabbit model of myocardial infarction.

Authors:  Yuanbo Feng; Feng Chen; Zhanlong Ma; Frederik Dekeyzer; Jie Yu; Yi Xie; Marlein Miranda Cona; Raymond Oyen; Yicheng Ni
Journal:  Theranostics       Date:  2013-12-01       Impact factor: 11.556

Review 7.  Role of cardiovascular magnetic resonance in acute coronary syndrome.

Authors:  Jan Bogaert; Ingo Eitel
Journal:  Glob Cardiol Sci Pract       Date:  2015-07-02

Review 8.  Contemporary cardiovascular imaging methods for the assessment of at-risk myocardium.

Authors:  W Benjamin Wince; Pal Suranyi; U Joseph Schoepf
Journal:  J Am Heart Assoc       Date:  2013-12-23       Impact factor: 5.501

Review 9.  Current clinical applications of cardiovascular magnetic resonance imaging.

Authors:  L Scholtz; A Sarkin; Z Lockhat
Journal:  Cardiovasc J Afr       Date:  2014 Jul-Aug       Impact factor: 1.167

10.  T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients.

Authors:  Heerajnarain Bulluck; Steven K White; Stefania Rosmini; Anish Bhuva; Thomas A Treibel; Marianna Fontana; Amna Abdel-Gadir; Anna Herrey; Charlotte Manisty; Simon M Y Wan; Ashley Groves; Leon Menezes; James C Moon; Derek J Hausenloy
Journal:  J Cardiovasc Magn Reson       Date:  2015-08-12       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.